vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $281.3M, roughly 1.2× Guardant Health, Inc.). PRA GROUP INC runs the higher net margin — 17.0% vs -45.7%, a 62.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 13.7%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-90.4M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 14.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
GH vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $333.4M |
| Net Profit | $-128.5M | $56.5M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 37.7% |
| Net Margin | -45.7% | 17.0% |
| Revenue YoY | 39.4% | 13.7% |
| Net Profit YoY | -15.8% | 206.3% |
| EPS (diluted) | $-1.01 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $333.4M | ||
| Q3 25 | $265.2M | $311.1M | ||
| Q2 25 | $232.1M | $287.7M | ||
| Q1 25 | $203.5M | $269.6M | ||
| Q4 24 | $201.8M | $293.2M | ||
| Q3 24 | $191.5M | $281.5M | ||
| Q2 24 | $177.2M | $284.2M | ||
| Q1 24 | $168.5M | $255.6M |
| Q4 25 | $-128.5M | $56.5M | ||
| Q3 25 | $-92.7M | $-407.7M | ||
| Q2 25 | $-99.9M | $42.4M | ||
| Q1 25 | $-95.2M | $3.7M | ||
| Q4 24 | $-111.0M | $18.5M | ||
| Q3 24 | $-107.8M | $27.2M | ||
| Q2 24 | $-102.6M | $21.5M | ||
| Q1 24 | $-115.0M | $3.5M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 37.7% | ||
| Q3 25 | -37.3% | -101.4% | ||
| Q2 25 | -45.9% | 29.6% | ||
| Q1 25 | -54.6% | 27.7% | ||
| Q4 24 | -62.4% | 32.1% | ||
| Q3 24 | -61.3% | 32.0% | ||
| Q2 24 | -56.8% | 31.4% | ||
| Q1 24 | -59.2% | 26.0% |
| Q4 25 | -45.7% | 17.0% | ||
| Q3 25 | -35.0% | -131.0% | ||
| Q2 25 | -43.0% | 14.7% | ||
| Q1 25 | -46.8% | 1.4% | ||
| Q4 24 | -55.0% | 6.3% | ||
| Q3 24 | -56.3% | 9.6% | ||
| Q2 24 | -57.9% | 7.6% | ||
| Q1 24 | -68.2% | 1.4% |
| Q4 25 | $-1.01 | $1.47 | ||
| Q3 25 | $-0.74 | $-10.43 | ||
| Q2 25 | $-0.80 | $1.08 | ||
| Q1 25 | $-0.77 | $0.09 | ||
| Q4 24 | $-0.90 | $0.47 | ||
| Q3 24 | $-0.88 | $0.69 | ||
| Q2 24 | $-0.84 | $0.54 | ||
| Q1 24 | $-0.94 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $104.4M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $979.9M |
| Total Assets | $2.0B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $104.4M | ||
| Q3 25 | $580.0M | $107.5M | ||
| Q2 25 | $629.1M | $131.6M | ||
| Q1 25 | $698.6M | $128.7M | ||
| Q4 24 | $525.5M | $105.9M | ||
| Q3 24 | $585.0M | $141.1M | ||
| Q2 24 | $933.7M | $118.9M | ||
| Q1 24 | $1.0B | $108.1M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $979.9M | ||
| Q3 25 | $-354.5M | $928.5M | ||
| Q2 25 | $-305.5M | $1.3B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | $1.1B | ||
| Q3 24 | $-60.1M | $1.2B | ||
| Q2 24 | $-1.6M | $1.1B | ||
| Q1 24 | $68.3M | $1.1B |
| Q4 25 | $2.0B | $5.1B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.3B | $5.4B | ||
| Q1 25 | $1.3B | $5.1B | ||
| Q4 24 | $1.5B | $4.9B | ||
| Q3 24 | $1.5B | $4.9B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.7B | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-85.5M |
| Free Cash FlowOCF − Capex | $-54.2M | $-90.4M |
| FCF MarginFCF / Revenue | -19.3% | -27.1% |
| Capex IntensityCapex / Revenue | 9.9% | 1.4% |
| Cash ConversionOCF / Net Profit | — | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-85.5M | ||
| Q3 25 | $-35.4M | $-10.1M | ||
| Q2 25 | $-60.3M | $-12.9M | ||
| Q1 25 | $-62.7M | $-52.6M | ||
| Q4 24 | $-64.5M | $-94.6M | ||
| Q3 24 | $-51.1M | $-35.0M | ||
| Q2 24 | $-94.0M | $-29.5M | ||
| Q1 24 | $-30.3M | $-73.0M |
| Q4 25 | $-54.2M | $-90.4M | ||
| Q3 25 | $-45.8M | $-11.3M | ||
| Q2 25 | $-65.9M | $-14.2M | ||
| Q1 25 | $-67.1M | $-53.5M | ||
| Q4 24 | $-83.4M | $-98.6M | ||
| Q3 24 | $-55.3M | $-36.1M | ||
| Q2 24 | $-99.1M | $-30.8M | ||
| Q1 24 | $-37.2M | $-73.5M |
| Q4 25 | -19.3% | -27.1% | ||
| Q3 25 | -17.3% | -3.6% | ||
| Q2 25 | -28.4% | -4.9% | ||
| Q1 25 | -33.0% | -19.8% | ||
| Q4 24 | -41.3% | -33.6% | ||
| Q3 24 | -28.9% | -12.8% | ||
| Q2 24 | -55.9% | -10.8% | ||
| Q1 24 | -22.1% | -28.8% |
| Q4 25 | 9.9% | 1.4% | ||
| Q3 25 | 3.9% | 0.4% | ||
| Q2 25 | 2.4% | 0.4% | ||
| Q1 25 | 2.2% | 0.3% | ||
| Q4 24 | 9.4% | 1.4% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 2.9% | 0.5% | ||
| Q1 24 | 4.1% | 0.2% |
| Q4 25 | — | -1.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | — | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | — | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
